FindTrial
Sign In

Cemiplimab REGN2810

DRUG5 trials

Sponsors

Sanofi

Conditions

LymphomaMalignant Solid TumorMetastatic NeoplasmNon-small Cell Lung CancerPlasma Cell MyelomaProstate Cancer

Phase 1

A First-in-human Study of the Safety, Pharmacokinetics, Pharmacodynamics and Anti-tumor Activity of SAR439459 Monotherapy and Combination of SAR439459 and Cemiplimab in Patients With Advanced Solid Tumors
CompletedNCT03192345
SanofiMalignant Solid Tumor
Start: 2017-06-09End: 2022-01-17Updated: 2024-08-07
Isatuximab in Combination With Cemiplimab in Relapsed/Refractory Multiple Myeloma (RRMM) Patients
CompletedNCT03194867
SanofiPlasma Cell Myeloma
Start: 2018-02-21End: 2023-04-05Updated: 2024-06-14
Isatuximab in Combination With REGN2810 (Cemiplimab) in Patients With Advanced Malignancies
TerminatedNCT03367819
SanofiNon-small Cell Lung Cancer, Prostate Cancer
Start: 2018-01-04End: 2021-03-10Updated: 2022-05-16
A Study of Isatuximab-based Therapy in Participants With Lymphoma
TerminatedNCT03769181
SanofiLymphoma
Start: 2018-12-11End: 2022-11-08Updated: 2025-09-23
A First-in-Human Dose Escalation and Expansion Study to Evaluate Intratumoral Administration of SAR441000 as Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors
TerminatedNCT03871348
SanofiMetastatic Neoplasm
Start: 2019-01-03End: 2024-02-21Updated: 2025-09-10

Related Papers

Abstract CT046: Clinical and translational study of the TGF-β monoclonal antibody SAR439459 in combination with the PD-1 inhibitor cemiplimab for patients (pts) with advanced solid tumors: Results from the phase 1b TACTIC trial
Cancer Research2025-04-25
Biomarker and pharmacodynamic activity of the transforming growth factor‐beta (<scp>TGFβ)</scp> inhibitor <scp>SAR439459</scp> as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors
Clinical and Translational Science2024-02-016 citations
New advances in cancer therapy targeting TGF-β signaling pathways
Molecular Therapy — Oncolytics2023-12-0127 citations
826 Differential effect of NKG2A blockade on peripheral and intra-tumoral CD8 T cell response induced by KISIMA – VSV-GP-TAg heterologous prime-boost vaccination
Regular and Young Investigator Award Abstracts2023-10-31
Abstract LB198: A first-in-human, open-label, multicenter study of intratumoral SAR441000 (mixture of cytokine encoding mRNAs), as monotherapy and in combination with cemiplimab in patients with advanced solid tumors
Cancer Research2023-04-1411 citations
Isatuximab in combination with cemiplimab in patients with relapsed/refractory multiple myeloma: A phase 1/2 study
Cancer Medicine2023-03-0312 citations
A phase 1/2, open‐label, multicenter study of isatuximab in combination with cemiplimab in patients with lymphoma
Hematological Oncology2022-10-179 citations
Safety and efficacy results from the expansion phase of the first-in-human study evaluating TGFβ inhibitor SAR439459 alone and combined with cemiplimab in adults with advanced solid tumors.
Journal of Clinical Oncology2022-06-0114 citations
Targeting CD38 and PD-1 with isatuximab plus cemiplimab in patients with advanced solid malignancies: results from a phase I/II open-label, multicenter study
Journal for ImmunoTherapy of Cancer2022-01-0142 citations
A Phase 1/2, Open-Label, Multicenter Study of Isatuximab in Combination with Cemiplimab in Patients with Lymphoma
Blood2021-11-051 citations
520 Preliminary biomarker and pharmacodynamic (PD) activity of the TGFβ inhibitor SAR439459, alone or in combination with cemiplimab, in a phase 1 clinical study in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts2021-11-013 citations
Abstract LB040: Targeting CD38 and PD-1 with isatuximab (Isa) plus cemiplimab (Cemi) in patients (pts) with advanced malignancies: Results from a Phase 1/2 open-label, multicenter study
Cancer Research2021-07-013 citations
Abstract 1909: Pan-TGF-β inhibition with PD-1 blockade as a combination treatment strategy to augment anti-tumor immune response in hepatocellular carcinoma
Cancer Research2021-07-01
Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGFβ inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.
Journal of Clinical Oncology2021-05-205 citations
Abstract 4451: Combination of local mRNA immunotherapy with systemic immune checkpoint blockade demonstrates anti-tumor activity across a diverse range of preclinical syngeneic tumor models
Cancer Research2020-08-157 citations
Abstract 773: Tumor-derived Extracellular Vesicles (EVs) expressing TGFb as potential biomarkers for anti-TGFb antibody activity and drug activity in liquid biopsy
Cancer Research2020-08-15
Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
OncoImmunology2020-01-0153 citations
Abstract 5550: Translational biomarkers for SAR439459, an anti-TGFβ antibody for cancer immunotherapy
Cancer Research2018-07-013 citations